SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Clements PJ, Becvar R, Drosos AA, Ghattas L, Gabrielli A. Assessment of gastrointestinal involvement. Clin Exp Rheumatol 2003; 21: S158.
  • 2
    Poirier T, Rankin M. Gastrointestinal manifestations of progressive systemic scleroderma based on a review of 364 cases. Am J Gastroenterol 1972; 58: 3044.
  • 3
    Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37: 126582.
  • 4
    Turner R, Lipshutz W, Miller W, Rittenberg G, Schumacher HR, Cohen S. Esophageal dysfunction in collagen disease. Am J Med Sci 1973; 265: 1919.
  • 5
    Stevens MB, Hookman P, Siegel C, Esterly JR, Shulman L, Hendrix T. Aperistalsis of the esophagus in patients with connective-tissue disorders and Raynaud's phenomenon. N Engl J Med 1964; 270: 121822.
  • 6
    Kahan A, Menkes CJ. Gastrointestinal involvement in systemic sclerosis [review]. Clin Dermatol 1994; 12: 25965.
  • 7
    Chang JT, Katzka DA. Gastroesophageal reflux disease, barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med 2004; 164: 14828.
  • 8
    Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus and esophageal cancer. JAMA 2002; 287: 197286.
  • 9
    Heath E, Limburg P, Hawk E, Forastiere AA. Adenocarcinoma of the esophagus: risk factors and prevention. Oncology 2000; 14: 50723.
  • 10
    Katzka D, Reynolds JC, Saul S, Plotkin A, Lang C, Ouyang A, et al. Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma. Am J Med 1987; 82: 4652.
  • 11
    Segel M, Campbell W, Medsger T, Roumm A. Systemic sclerosis (scleroderma) and esophageal adenocarcinoma: is increased patient screening necessary? Gastroenterology 1985; 89: 4858.
  • 12
    Subcomittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 13
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis [editorial]. J Rheumatol 1988; 15: 2025.
  • 14
    Matucci-Cerinic M, D'Angelo S, Denton CP, Vlachoyiannopoulos P, Silver R. Assessment of lung involvement. Clin Exp Rheumatol 2003; 21 Suppl 29: S1923.
  • 15
    Cameron A, Payne W. Barrett's esophagus occurring as a complication of scleroderma. Mayo Clin Proc 1978; 53: 6125.
  • 16
    Agha F, Dabich L. Barrett's esophagus complicating scleroderma. Gastrointest Radiol 1985; 20: 3259.
  • 17
    Anderson M, Seymour E. Association of Barrett's esophagus and scleroderma. South Med J 1987; 80: 7645.
  • 18
    Chang CP, Huang Y, Tsay S, Lai K, Lee S. Primary biliary cirrhosis and scleroderma complicated by Barrett's oesophagus. S Afr Med J 1991; 79: 3978.
  • 19
    Dill J. Barrett's epithelium in scleroderma. Gastrointest Endosc 1983; 29: 2967.
  • 20
    Halpert R, Laufer I, Thompson J, Feczko P. Adenocarcinoma of the esophagus in patients with scleroderma. Am J Roentgenol 1983; 140: 9207.
  • 21
    Ilan Y, Shouval D, Galun E, Goldin E, Ligumsky M, Friedman G, et al. Esophageal malignancy after liver transplantation in a patient with Barrett's esophagus. Scand J Gastroenterol 1996; 31: 4156.
  • 22
    Lambert DR, Llanrza P, Gaglani R, Lach R, Beaver W. Esophageal-atrial fistula. J Clin Gastroenterol 1987; 9: 3459.
  • 23
    McKinley M, Sherlock P. Barrett's esophagus with adenocarcinoma in scleroderma. Am J Gastroenterol 1984; 79: 4389.
  • 24
    Maekawa Y, Nogami R. A case of progressive systemic sclerosis associated with sarcoidosis and esophageal adenocarcinoma. J Dermatol 1993; 20: 458.
  • 25
    Navon P, Klar A, Hurvitz H, Adler S, Branski D. Barrett's esophagus in a young patient with Raynaud's phenomenon. J Rheumatol 1991; 18: 17356.
  • 26
    Niv Y, Abu-Avid S, Yelin A, Liberman Y. Barrett's epithelium and esophageal adenocarcinoma in scleroderma. Am J Gastroenterol 1988; 83: 7923.
  • 27
    Sprung J, Gibb P. Dysplasic Barrett's esophagus in scleroderma. Am J Gastroenterol 1985; 80: 51822.
  • 28
    Szigeti N, Fabian G, Gomori E, Czirjak L. Barrett esophagus in systemic sclerosis. Orv Hetil 2001; 142: 6714.
  • 29
    Marie I, Dominique S, Levesque H, Ducrotte P, Denis P, Hellot MF, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001; 45: 34654.
  • 30
    Recht M, Levine M, Katzka D, Reynolds J, Saul S. Barrett's esophagus in scleroderma: increased prevalence and radiographic findings. Gastrointest Radiol 1988; 13: 15.
  • 31
    Weston S, Thumshirn M, Wiste J, Camilleri M. Clinical and upper gastrointestinal motility features in systemic sclerosis and related disorders. Am J Gastroenterol 1998; 93: 10859.
    Direct Link:
  • 32
    Atkinson M, Summerling M. Oesophageal changes in systemic sclerosis. Gut 1966; 7: 4028.
  • 33
    Modlin I, Kidd M. GERD 2003: issues from the past and consensus for the future. Drugs Today (Barc) 2004; 40 Suppl A: 38.
  • 34
    Hendel L, Hage E, Hendel J, Stentoft P. Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther 1992; 6: 56577.
  • 35
    Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, Spechler S, et al. Review of the diagnosis and management of Barrett's esophagus: the AGA Chicago workshop. Gastroenterol 2004; 127: 31030.
  • 36
    Wu JC, Chan FK, Ching JY, Leung WK, Hui Y, Leong R, et al. Effect of Helicobacter pylori on treatment of gastroesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut 2004; 2: 1749.
  • 37
    Zhang J, Chen XL, Wang KM, Guo XD, Zuo AL, Gong J. Relationship of gastric Helicobacter pylori infection to Barrett's esophagus and gastroesophageal reflux disease in Chinese. World J Gastroenterol 2004; 5: 6725.
  • 38
    Abe Y, Ohara S, Koike T, Sekine H, Iijima K, Kawamura M, et al. The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with Barrett's esophagus in Japan. Am J Gastroenterol 2004; 77: 121321.
    Direct Link:
  • 39
    Yazawa N, Fujimoto M, Kikuchi K, Kubo M, Ihn H, Sato S, et al. High seroprevalence of Helicobacter pylori infection in patients with systemic sclerosis: association with esophageal involvement. J Rheumatol 1998; 25: 6503.
  • 40
    Haggit RC, Tryzelaar J, Ellis FM, Ellis FH, Colcher H. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol 1978; 70: 15.
  • 41
    Sarr M, Hamilton S, Marrone G, Cameron J. Barrett's esophagus: its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux. Am J Surg 1985; 149: 18793.
  • 42
    Pech O, May A, Gossner L, Rabenstein T, Ell C. Management of pre-malignant and malignant lesions by endoscopic resection. Best Pract Res Clin Gastroenterol 2004; 18: 6176.
  • 43
    Bassotti G, Battaglia E, Debernardi V, Germani U, Quiriconi F, Dughera L, et al. Esophageal dysfunction in scleroderma: relationship with disease subsets. Arthritis Rheum 1997; 40: 22529.
  • 44
    Fulp S, Castell D. Scleroderma esophagus. Dysphagia 1990; 5: 20410.
  • 45
    Furst DE, Clements PJ, Saab M, Sterz MG, Paulus HE. Clinical and serological comparison of 17 chronic progressive systemic sclerosis and 17 CREST syndrome patients for sex, age, and disease duration. Ann Rheum Dis 1984; 43: 794801.